A method of promoting wound healing in a patient, the method comprising applying on a wound a biodegradable amino-acid based polymer.

A dressing for treating a tissue site with negative pressure may comprise a cover having an adhesive, a manifold, a perforated polymer film, and a perforated silicone gel having a treatment aperture. The cover, the manifold, the perforated polymer film, and the perforated silicone gel may be assembled in a stacked relationship with the cover and the perforated silicone gel enclosing the manifold. The perforated polymer film may be at least partially exposed through the treatment aperture, and at least some of the adhesive may be exposed through the perforated silicone around the treatment aperture.

A dressing for treating a tissue site with negative pressure may comprise a cover having an adhesive, a manifold, a perforated polymer film, and a perforated silicone gel having a treatment aperture. The cover, the manifold, the perforated polymer film, and the perforated silicone gel may be assembled in a stacked relationship with the cover and the perforated silicone gel enclosing the manifold. The perforated polymer film may be at least partially exposed through the treatment aperture, and at least some of the adhesive may be exposed through the perforated silicone around the treatment aperture.

In various exemplary embodiments, the present disclosure provides organohydrogel fibers and a process for making the organohydrogel fibers. The organohydrogel fibers have a hydrophobic phase dispersed in a hydrophilic phase. The organohydrogel fibers contain at least one hydrophobic active pharmaceutical ingredient (API), and at least one hydrophilic API. The organohydrogel fibers can be formed into a non-woven or 3D printed patch and a replaceable backing can be attached to the patch to make an effective wound dressing. The wound dressing can deliver active pharmaceutical ingredients to the wound over a period of multiple days.

In various exemplary embodiments, the present disclosure provides organohydrogel fibers and a process for making the organohydrogel fibers. The organohydrogel fibers have a hydrophobic phase dispersed in a hydrophilic phase. The organohydrogel fibers contain at least one hydrophobic active pharmaceutical ingredient (API), and at least one hydrophilic API. The organohydrogel fibers can be formed into a non-woven or 3D printed patch and a replaceable backing can be attached to the patch to make an effective wound dressing. The wound dressing can deliver active pharmaceutical ingredients to the wound over a period of multiple days.

The present invention provides a hemostatic porous composite sponge comprising: i) a matrix of a biomaterial; and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that said polymeric component is coated onto a surface of said matrix of a biomaterial, or said matrix is impregnated with said polymeric material, or both.

The present invention provides a hemostatic porous composite sponge comprising: i) a matrix of a biomaterial; and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that said polymeric component is coated onto a surface of said matrix of a biomaterial, or said matrix is impregnated with said polymeric material, or both.

Organosilicon quaternary ammonium compounds, their formulations, including powdered and solid formulations, and methods of use to treat infections in humans and animals.

Organosilicon quaternary ammonium compounds, their formulations, including powdered and solid formulations, and methods of use to treat infections in humans and animals.

Novel compositions and systems for closure of wounds are disclosed. The compositions provide devices of improved flexibility and elasticity and are readily applied to wound sites or over wound closure devices. The present invention is also directed to a novel platinum catalyst for use in such compositions. The catalyst provides for rapid curing on topical surfaces such as skin and bonds to such surfaces in about 2-5 minutes.